{"id":72093,"date":"2026-05-01T05:21:09","date_gmt":"2026-05-01T05:21:09","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/72093\/"},"modified":"2026-05-01T05:21:09","modified_gmt":"2026-05-01T05:21:09","slug":"chcete-moderni-lek-na-rakovinu-musite-do-usa-v-evrope-se-ho-prodavat-nevyplati-upozornuje-firma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/72093\/","title":{"rendered":"Chcete modern\u00ed l\u00e9k na rakovinu? Mus\u00edte do USA, v Evrop\u011b se ho prod\u00e1vat nevyplat\u00ed, upozor\u0148uje firma"},"content":{"rendered":"

Evropa m\u00e1 na vybranou. Chce z\u016fstat l\u00eddrem ve farmaceutick\u00e9m pr\u016fmyslu, nebo se za\u010dne st\u00e1le v\u00edce spol\u00e9hat na to, \u017ee j\u00ed Spojen\u00e9 st\u00e1ty a \u010c\u00edna jen umo\u017en\u00ed z\u00edskat p\u0159\u00edstup k\u00a0l\u00e9k\u016fm, kter\u00e9 se budou ve st\u00e1le v\u011bt\u0161\u00edm m\u011b\u0159\u00edtku vyv\u00edjet pr\u00e1v\u011b tam? To je podle v\u00fdkonn\u00e9ho \u0159editele nejv\u011bt\u0161\u00ed soukrom\u00e9 (tedy nikoli ve\u0159ejn\u011b obchodovan\u00e9) farmaceutick\u00e9 spole\u010dnosti sv\u011bta zcela kl\u00ed\u010dov\u00e1 a z\u00e1sadn\u00ed ot\u00e1zka, kterou si mus\u00ed star\u00fd kontinent zodpov\u011bd\u011bt. \u201eBez reforem se staneme z\u00e1visl\u00ed na \u010c\u00edn\u011b,\u201c uvedl Shashank Deshpande, \u0161\u00e9f spole\u010dnosti Boehringer Ingelheim pro britsk\u00fd list Financial Times<\/a>.<\/p>\n

V\u00fdkonn\u00fd \u0159editel nejv\u011bt\u0161\u00ed soukrom\u00e9 farmaceutick\u00e9 spole\u010dnosti sv\u011bta Boehringer Ingelheim Shashank Deshpande varoval, \u017ee Evropa se nach\u00e1z\u00ed na pomysln\u00e9 k\u0159i\u017eovatce. A to pr\u00e1v\u011b v\u00a0oblasti farmaceutick\u00e9ho pr\u016fmyslu.<\/p>\n

Star\u00fd kontinent toti\u017e podle n\u011bj riskuje, \u017ee v\u00a0p\u0159\u00edstupu k\u00a0inovativn\u00edm l\u00e9k\u016fm zaostane nejen za USA, ale tak\u00e9 za \u010c\u00ednou. Nikoli proto, \u017ee by Evropan\u00e9 ztratili schopnost zkoumat nov\u00e9 l\u00e9\u010div\u00e9 p\u0159\u00edpravky. N\u00fdbr\u017e proto, \u017ee se zde farmaceutick\u00fdm spole\u010dnostem bude st\u00e1le m\u00e9n\u011b vypl\u00e1cet do toho investovat.<\/p>\n

Evropa m\u00e1 st\u00e1le na v\u00fdb\u011br<\/p>\n

\u201eEvropa m\u00e1 na v\u00fdb\u011br. Chceme i nad\u00e1le b\u00fdt l\u00eddrem ve farmaceutick\u00e9m pr\u016fmyslu, nebo chceme toto odv\u011btv\u00ed p\u0159enechat USA a zejm\u00e9na \u010c\u00edn\u011b, kter\u00e1 se rychle rozv\u00edj\u00ed, pokud jde o farmaceutick\u00e9 inovace?\u201c polo\u017eil Deshpande ot\u00e1zku v\u00a0rozhovoru pro britsk\u00fd list Financial Times.<\/p>\n

V\u00a0\u010dem je podle n\u011bj probl\u00e9m? V\u00a0tom, \u017ee evropsk\u00e9 syst\u00e9my ve\u0159ejn\u00e9ho zdravotnictv\u00ed nejsou ochotny platit firm\u00e1m za tyto l\u00e9ky dost na to, aby jejich v\u00fdrobci do v\u00fdzkumu a v\u00fdvoje investovali pr\u00e1v\u011b v\u00a0Evrop\u011b.<\/p>\n

\u201eBez zm\u011bny tohoto p\u0159\u00edstupu a reformy syst\u00e9m\u016f by se farmaceutick\u00fd sektor v\u00a0Evrop\u011b mohl st\u00e1t z\u00e1visl\u00fdm pr\u00e1v\u011b zejm\u00e9na na \u010c\u00edn\u011b. A to v\u00a0dob\u011b, kdy u\u017e jsme na \u010c\u00edn\u011b, ale tak\u00e9 Indii superz\u00e1visl\u00ed, pokud se jedn\u00e1 o generick\u00e9 l\u00e9ky,\u201c dodal \u0161\u00e9f spole\u010dnosti Boehringer Ingelheim.<\/p>\n

Deshpande rovn\u011b\u017e upozornil, \u017ee podobnou obavu vyj\u00e1d\u0159ili i dal\u0161\u00ed \u0161\u00e9fov\u00e9 evropsk\u00fdch farmaceutick\u00fdch spole\u010dnost\u00ed. A to pot\u00e9, co americk\u00fd prezident Donald Trump za\u010dal na farmaceutick\u00fd sektor v\u00a0USA tla\u010dit, aby sn\u00ed\u017eil ceny l\u00e9k\u016f na p\u0159edpis pro americk\u00e9 poji\u0161t\u011bnce. Evropa by podle Desphpandeho m\u011bla Trumpovy politiky vyu\u017e\u00edt a v\u00fddaje na l\u00e9ky na p\u0159edpis za\u010d\u00edt zvy\u0161ovat.<\/p>\n

Mohlo by v\u00e1s zaj\u00edmat<\/p>\n


\n \"\"
\n <\/a><\/p>\n

Vyvinuto v\u00a0Evrop\u011b, dostupn\u00e9 v USA<\/p>\n

Jako p\u0159\u00edklad Deshpande pro list Financial Times zm\u00ednil p\u0159\u00edpravek Hernexeos, kter\u00fd se pod\u00e1v\u00e1 jako l\u00e9k na rakovinu plic. Spole\u010dnost Boehringer Ingelheim jej uvedla na trh ve Spojen\u00fdch st\u00e1tech, \u010c\u00edn\u011b a Japonsku, ale nikoli v\u00a0Evrop\u011b. D\u016fvodem je pr\u00e1v\u011b to, \u017ee evropsk\u00e9 syst\u00e9my ve\u0159ejn\u00e9ho zdravotnictv\u00ed za tento p\u0159\u00edpravek plat\u00ed m\u00e1lo.<\/p>\n

\u201eV N\u011bmecku a v\u00a0Evrop\u011b, kde jsme tento l\u00e9k vynalezli, nen\u00ed prim\u00e1rn\u011b k dispozici kv\u016fli tomu, \u017ee nen\u00ed za\u0159azen mezi l\u00e9ky hrazen\u00e9, proto\u017ee mus\u00edme prov\u00e9st dal\u0161\u00ed studii s aktivn\u00edm kompar\u00e1torem, abychom dos\u00e1hli p\u0159ijateln\u00e9 ceny, kterou u\u017e by syst\u00e9m ve\u0159ejn\u00e9ho zdravotnictv\u00ed zaplatil,\u201c \u0159ekl Deshpande.<\/p>\n

\u201ePokud se v Evrop\u011b objev\u00ed lid\u00e9 s\u00a0dan\u00fdm typem rakoviny, jejich jedinou \u0161anc\u00ed na u\u017e\u00edv\u00e1n\u00ed tohoto l\u00e9ku je let\u011bt do USA. Up\u0159\u00edmn\u011b \u0159e\u010deno, nikomu to tady nedok\u00e1\u017eu vysv\u011btlit. Je to \u0161koda,\u201c posteskl si \u0161\u00e9f spole\u010dnosti Boehringer Ingelheim.<\/p>\n","protected":false},"excerpt":{"rendered":"Evropa m\u00e1 na vybranou. Chce z\u016fstat l\u00eddrem ve farmaceutick\u00e9m pr\u016fmyslu, nebo se za\u010dne st\u00e1le v\u00edce spol\u00e9hat na to,…\n","protected":false},"author":2,"featured_media":72094,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[23744,202,109,108,106,17251,8487,1617,2811,3486],"class_list":{"0":"post-72093","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-evropa","8":"tag-boehringer-ingelheim","9":"tag-cina","10":"tag-europa","11":"tag-europe","12":"tag-evropa","13":"tag-farmaceuticke-firmy","14":"tag-farmaceuticky-prumysl","15":"tag-leky","16":"tag-rakovina","17":"tag-rakovina-plic"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116497644462162587","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/72093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=72093"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/72093\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/72094"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=72093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=72093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=72093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}